Case-Based Update on Hypoparathyroidism
Case-Based Update on Hypoparathyroidism
Friday, September 9, 2016 | 6:00-8:00 PM PST
Washington State Convention Center, Room 6AB
This course is a live CME-certified ancillary symposium presented at Clinical Endocrinology Update 2016, held in Seattle, Washington, September 8-10, 2016. CEU 2016 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).
This activity is supported by an educational grant from Shire.
Steven Harris, MD, FACP; University of California, San Francisco
Lynn Kohlmeier, MD; Spokane Osteoporosis
Susan Ott, MD; University of Washington
Nelson Watts, MD; Mercy Health
This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with bone disorders.
Upon completion of this educational activity, learners will be better able to:
- Describe the pathophysiology and differential diagnosis of hypoparathyroidism
- Identify the clinical manifestations of hypoparathyroidism
- Understand the mechanism and utility of new and emerging therapies in the management of hypoparathyroidism
- Develop safe and effective treatment plans for patients with hypoparathyroidism
Steven Harris, MD, FACP – Program Director
Clinical Professor of Medicine
University of California, San Francisco Medical Center
San Francisco, CA
Lynn Kohlmeier, MD
Endocrinology and Metabolic Bone
Spokane Internal Medicine
Spokane Osteoporosis, Director
Washington Osteoporosis Coalition
Susan Ott, MD
Professor of Medicine
Metabolism, Endocrinology and Nutrition
University of Washington
Department of Medicine
Nelson Watts, MD
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Steven Harris, MD, FACP: Speaker, Shire
Susan M Ott, MD: Speaker, Amgen
Nelson Watts, MD: Research Support, Shire; Consultant, Shire; Speaker, Shire
The faculty reported no relevant financial relationships: Lynn Kohlmeier, MD
The following SPC member who planned and reviewed content for this activity reported the following financial relationships: E Michael Lewiecki, MD: Advisory Board, Amgen, Merck, Eli Lilly, Radius Health, Shire, and Alexion; Speaker, Shire; Research Grant Support, Amgen, Eli Lilly, Merck
The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon Medtronic, Novo Nordisk, Sanofi Aventis; Consultant, Novo Nordisk, Eli Lilly, Janssen, Dexcom
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Alan Kelly, MD: Research Support, Novo Nordisk; Speaker, Novo Nordisk, Boehringer Ingelheim
Lisa Nachtigall, MD: Consultant, Pfizer, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim, Pfizer
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships: Giuseppe Barbesino, MD; Natalie Cusano, MD; Joan Han, MD; Connie Newman, MD; Amy Rothberg, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
- 2.00 AMA PRA Category 1 Credits™
- 2.00 CME Certificate of Participation